Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FIB918
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : McQuade Center
Deal Size : Undisclosed
Deal Type : Collaboration
Fibrocor Partners with McQuade Center for R&D to Advance Alport Syndrome Program
Details : The collaboration aims to support the clinical development of Fibrocor's FIB918, a monoclonal antibody. Currently, it is being evaluated in the IND-enabling phase for the treatment of Alport Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 05, 2024
Lead Product(s) : FIB918
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : McQuade Center
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
